Visudyne® in Occult (VIO)

Summary

The purpose of this study is to demonstrate that Visudyne therapy in patients who have occult with no classic subfoveal choroidal neovascularization (CNV) lesions will, with an acceptable safety profile, significantly reduce the risk of vision loss compared with placebo (sham treatment).

Timeline

Start

2002-03

Primary completion

—

Completion

2005-08

Outcome

Missed primary endpoint

paper The differences between the two groups in the primary efficacy variables were not significant. PMID 19530976 ↗

Publications

• Kaiser PK; Visudyne In Occult CNV (VIO) study group. Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. Curr Med Res Opin. 2009 Aug;25(8):1853-60. doi: 10.1185/03007990903038616.

Drugs

Indications